Previous 10 | Next 10 |
2024-02-13 16:06:50 ET More on G1 Therapeutics G1 Therapeutics: New Financials And Big Data Readout Alert G1 Therapeutics: Flying Low, Too Low G1 Therapeutics stock dives 36% post-market on P3 study update Seeking Alpha’s Quant Rating on G1 Therapeutic...
A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 8.2% to $4.695 on volume of 175,998,839 shares PROSHARES TRUST (SQQQ) rose 6.5% to $11.995 on volume of 143,217,194 shares Ohmyhome Limited (OMH) rose 105.6% to $2.55 on volume o...
2024-02-13 12:37:54 ET Gainers: Digital Brands Group ( DBGI ) +141% . Ohmyhome Ltd ( OMH ) +125% . ARB IOT Group Ltd ( ARBB ) +108% . MicroCloud Hologram ( HOLO ) +66% . Verde Clean Fuels ( VGAS ) +40% . Beamr Imaging Ltd ( ...
2024-02-13 10:00:06 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Communication Services, Info Tec...
2024-02-13 08:28:58 ET More on premarket losers Arm Holdings: Irrational Exuberance To The Max Arm Holdings: Shares Surge As GenAI Momentum Drives Massive Earnings Beat Arm Holdings: Why The Fiscal Q3 Earnings Foretell Change Arm Holdings surges as investors ...
2024-02-12 17:13:12 ET More on G1 Therapeutics G1 Therapeutics: New Financials And Big Data Readout Alert G1 Therapeutics: Flying Low, Too Low Seeking Alpha’s Quant Rating on G1 Therapeutics Historical earnings data for G1 Therapeutics Financia...
2024-02-12 16:57:21 ET Gainers: ZoomInfo Technologies ( ZI ) +19% . TripAdvisor ( TRIP ) +12% . Ramaco Resources ( METC ) +5% . Veritone ( VERI ) +4% . Regis Corporation ( RGS ) +4% . Losers: G1 Therapeutics ( GTH...
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that the independent Data Monitoring Committee (DMC) recommended continuation of the pivotal Phase 3 trial (PRESERVE 2), evaluating trila...
2024-01-09 07:55:26 ET Summary G1 Therapeutics has provided pipeline updates, including encouraging preliminary overall survival data from a phase 2 study of trilaciclib in combination with sacituzumab govitecan for advanced triple-negative breast cancer. The company aims to pursu...
- Initial Data from the Ongoing Phase 2 Trial in Combination with the Antibody-Drug Conjugate (ADC) Sacituzumab Govitecan (SG) Suggest a Potentially Meaningful Improvement in Overall Survival (OS) for Patients Receiving Trilaciclib - - COSELA® (trilaciclib) Vial Volume Growth Accelerat...
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...
RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug discovery and development company, announced a global licensing agreement (excluding t...